Last reviewed · How we verify
CI-581-b
CI-581-b is a dissociative anesthetic that acts as an NMDA receptor antagonist to produce rapid-onset anesthesia and analgesia.
CI-581-b is a dissociative anesthetic that acts as an NMDA receptor antagonist to produce rapid-onset anesthesia and analgesia. Used for Anesthesia induction and maintenance, Procedural sedation and analgesia.
At a glance
| Generic name | CI-581-b |
|---|---|
| Sponsor | New York State Psychiatric Institute |
| Drug class | NMDA receptor antagonist / Dissociative anesthetic |
| Target | NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia / Psychiatry |
| Phase | Phase 3 |
Mechanism of action
CI-581-b blocks N-methyl-D-aspartate (NMDA) glutamate receptors, which interrupts pain signal transmission and produces dissociative anesthesia characterized by preserved airway reflexes and analgesia. This mechanism allows for procedural sedation and anesthesia while maintaining spontaneous respiration and protective airway responses.
Approved indications
- Anesthesia induction and maintenance
- Procedural sedation and analgesia
Common side effects
- Dissociative effects / emergence reactions
- Increased blood pressure
- Increased heart rate
- Nausea and vomiting
- Dizziness
Key clinical trials
- Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer (EARLY_PHASE1)
- Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression (PHASE2)
- Ketamine-assisted Therapy for Advanced GI Cancer (PHASE4)
- Magnesium Sulphate Versus Ketamine as an Adjuvant to Bupivacaine in Pectoral Nerve Block During Mastectomy (PHASE2)
- Ketamine for the Treatment of Opioid Use Disorder and Depression (PHASE2)
- The Postoperative Lidocaine and Ketamine Effects on Morphine Requirement in Bariatric Surgery
- Dexametomedine Versus Ketamine as an Adjuvant in Erector Spinae Block for Perioperative Thoracotomy Pain Control (PHASE4)
- Facilitating Rapid Naltrexone Initiation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CI-581-b CI brief — competitive landscape report
- CI-581-b updates RSS · CI watch RSS
- New York State Psychiatric Institute portfolio CI